Spliceosome gene mutations are among the 50--60 driver mutations underlying myelodysplastic syndromes (MDSs).^[@bib1]^ *U2AF1* mutations for example have been reported to occur in up to 16% of primary myelofibrosis (PMF), and was found to be associated with anemia and thrombocytopenia in PMF.^[@bib2]^ We could show that spliceosome gene mutations are already present in early stages of PMF before fibrosis and cytopenia become manifest.^[@bib3]^ Recently, a negative association between mutations of calreticulin (*CALR*) and spliceosome genes has been described.^[@bib4]^

*CALR* is a Ca^2+^-binding protein, which was found in 2013 to be mutated in *JAK2*- or *MPL*-unmutated PMF and essential thrombocythemia.^[@bib5],[@bib6]^ Mutations were mutually exclusive of *JAK2* or MPL mutations. *JAK2*-mutated and triple-negative patients were shown to have significantly shorter survival periods in comparison to those with somatic frameshift mutations in the *CALR* gene.^[@bib4],[@bib5]^ Tefferi *et al.*^[@bib4]^ described significantly lower frequency of spliceosome mutations in *CALR*-mutated cases and attributed the lower incidence of anemia to the lower frequency of *U2AF1* mutations.

Up to now allogeneic hematopoietic stem cell transplantation (AHSCT) represents the only curative treatment modus for patients with PMF.^[@bib7]^ Selection of patients suitable for this kind of treatment is performed according to prognostic scoring and tolerable risks of individual patients. Data of Heuser *et al.*^[@bib8]^ suggest a better overall survival for *CALR*-mutated PMF patients after AHSCT.

In this study, we analyzed 69 patients with PMF grades of fibrosis 2--3 ([Table 1](#tbl1){ref-type="table"}) who have undergone allogenic stem cell transplantation for *JAK2*, *MPL*, *CALR* and spliceosome gene mutations (*SRSF2*, *U2AF1* and *SF3B1*) using bone marrow trephines and pyrosequencing as described.^[@bib9]^

*CALR* was rarely combined with splice factor gene mutations (10.5% of all *CALR*-mutated cases; negative correlation, *P*=0.0418) and these combinations were restricted to *SF3B1*. Combined mutations with *U2AF1* and *SRSF2* could not be found at all. The frequency of accompanying splice factor gene mutations in *CALR*-mutated patients was significantly lower than that in patients without a *CALR* mutation (21/50, 42% *P*=0.04) or in those with a *JAK2* mutation (18/41, 44% *P*=0.04). *U2AF1* was the most frequent splice factor gene mutation associated with *JAK*^V617F^. In PMF, splice factor gene mutations were associated significantly more often with a *JAK2* mutation than with a *CALR* mutation (*P*\<0.00005; Fisher\'s exact tests).

In our cohort 7 patients (10%) revealed neither *JAK2* nor *MPL* or *CALR* mutation. In the 'triple-negative\' subgroup of PMF, exclusively mutations of *SRSF2* occurred (n=2), but no alterations of *U2AF1* and *SF3B1* could be observed ([Table 1](#tbl1){ref-type="table"}).

Because of the low number of *MPL*-mutated cases in this series additional samples of PMF with bone marrow fibrosis grade 2--3 and known *MPL* mutation (*n*=20, all *JAK2* exon 14 wild type) were investigated for combination with splice factor gene mutations. Among the 20 *MPL*-mutated cases 10 samples exhibited splice factor gene mutations (50%). Three samples revealed mutation of *U2AF1* (15%), six of *SRSF2* (30%) and one of *SF3B1* (5%), respectively. Consequently, MPL-mutated PMF cases appear to carry splice factor gene mutations with a similar frequency as *JAK2*-mutated cases. *CALR*-mutated cases behave different from *JAK2*- and *MPL*-mutated cases in that splice factor gene mutations occur significantly rarer (*P*\<0.005 for *MPL*) and only combinations with *SF3B1* could be found.

After a median follow-up of 18 months four patients suffered molecular and histopathological relapse. Interestingly, the recurrent disease was different from the primary MPN and differences with regard to histopathology as well as to molecular aberrations could be observed. In two patients the bone marrow displayed reduced myelofibrosis (\<MF2) but cytopenia was still evident (Patient 3 and 4 in [Table 2](#tbl2){ref-type="table"}). *JAK2* mutation was no longer detectable in these cases but splice factor gene mutations persisted and as shown for *SRSF2* to a similar allelic burden as in the bone marrow before AHSCT. Bone marrow biopsy in one case (patient 3) still revealed atypical megakaryocytes and myelofibrosis (MF1), consistent with relapse of PMF but with reduction of fibrosis ([Table 2](#tbl2){ref-type="table"}). In another case with persisting *U2AF1* mutation after AHSCT histology showed a different picture more reminiscent of MDS with excess of blasts, and megakaryocytes did not show the atypia anymore characteristic for PMF (patient 4, [Table 2](#tbl2){ref-type="table"}). In patient No 1 *JAK2* mutation was still detectable, but with a reduced allelic burden (15%) compared with the primary biopsy (80%), whereas *SRSF2* mutation remained on an identical level of 50% ([Table 2](#tbl2){ref-type="table"}). In this case myelofibrosis was also diminished 1 year after AHSCT (MF grade 3 to MF grade 1) but increased again to MF grade 2 after 4 years. In addition, there was one case with persisting *JAK2* mutation and loss of splice factor gene mutations (*U2AF1*) after AHSCT (patient 2).

Our results show that PMF with high-risk scores eligible for AHSCT represents a molecularly heterogeneous disease despite uniform histopathology of bone marrow with atypical megakaryocytic proliferation and evident myelofibrosis. Cytopenia which is used for risk stratification and which is the dominant cause to treat patients with AHSCT appears to be associated in a considerable proportion of PMF cases with splice factor gene mutations. In these cases fibrotic obliteration of bone marrow spaces seems not to be the only cause of cytopenia. Splice factor gene mutations are significantly more frequently combined with *JAK2* and *MPL* mutations than with *CALR* mutation. Furthermore, different hematopoietic clones proliferate in PMF giving rise to a molecular mosaic. After AHSCT of PMF relapses may uncover the underlying clonal mosaic and different diseases may emerge. Despite reduction of myelofibrosis and eradication of the *JAK2*^V617F^ clone cytopenia may persist. The molecular mosaic in myeloproliferative neoplasms has been demonstrated to be the result of both independent clones proliferating in parallel as well as clonal evolution with stepwise acquisition of different mutations by a single neoplastic clone.^[@bib10]^ Molecular monitoring of patients having undergone AHSCT for PMF should not be restricted to *JAK2*, *MPL* or *CALR*, but all mutations present in the primary fibrotic neoplastic myeloproliferation should be included to interpret abnormal blood values after AHSCT. The apparently better prognosis of *CALR*-mutated PMF.^[@bib4],[@bib5]^ including cases treated with AHSCT^[@bib8]^ may at least in part be attributable to a less likely association with splice factor gene mutations.
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###### PMF patients treated by allogeneic stem cell transplantation

                                              *Patients with AHSCT*  *Patients with splice factor gene mutations*   *Patients with follow-up biopsies* (n*=52*) *and molecular relapse*
  ------------------------------------------ ----------------------- ---------------------------------------------- ---------------------------------------------------------------------
  Number of patients (%)                               69            23 (33%)                                       4 (7.7%)
  Median age, years (range)                       65.5 (33--75)      66 (44--76)                                    64 (61--76)
  Male                                                 42            15                                             3
  Female                                               27            8                                              1
  *JAK2*^V617F^ (%)                                41 (59.4%)        18 (78.2%)                                     3
                                                                     5 *JAK2*/*SRSF2*                                
                                                                     10 *JAK2*/*U2AF1*                               
                                                                     3 *JAK2*/*SF3B1*                                
  *MPL* (exon 10)                                   2 (2.9%)         1 (1.4%)                                       0
                                                                     1 *MPL*/*SF3B1*                                 
  Calreticulin (exon 9) (%)                        19 (27.5%)        2 (8.7%)                                       0
                                                                     2 *CALR*/*SF3B1*                                
  *SRSF2* (exon 1) (%)                              7 (10.1%)        7 (21.8%)                                      2
                                                                     5 *SRSF2*/*JAK2*                                
                                                                     2 *SRSF2*/TN                                    
  *U2AF1* (exons 2, 6) (%)                          9 (13.0%)        10 (43.5%)                                     1
                                                                     10 *U2AF1*/*JAK2*                               
  *SF3B1* (exons 14, 15)                            6 (8.7%)         6 (26.1%)                                      0
                                                                     3 *SF3B1*/*JAK2*                                
                                                                     1 *SF3B1*/*MPL*                                 
                                                                     2 *SF3B1*/*CALR*                                
  Median time of follow-up biopsy (months)             13            14                                             18
  Myelofibrosis grade 2 and 3 (%)                   69 (100%)        23 (100%)                                      2 (50%)

Abbreviation: AHSCT, allogeneic hematopoietic stem cell transplantation; PMF, primary myelofibrosis; TN, triple negative.

###### Molecular relapses after allogeneic stem cell transplantation of PMF

                                *P1*    *P1+AHSCT*     *P2*      *P2+AHSCT*   *P3*    *P3+AHSCT*     *P4*      *P4+AHSCT*
  ---------------------------- ------- ------------ ----------- ------------ ------- ------------ ----------- ------------
  *JAK2*                        V617F     V617F        V617F       V617F      V617F       WT         V617F         WT
                                 80%       15%          50%         14%        14%                    27%           
  *SRSF2*                       P95H       P95H         WT           WT       P95H       P95H         WT           WT
                                 50%       50%                                 30%       40%                        
  *U2AF1*                        WT         WT       Q157P 40%       WT        WT         WT       Q157P 40%   Q157P 40%
  Myelofibrosis                  MF3       MF2          MF3         MF3        MF3       MF1          MF3         MF0
  Hemoglobin (g/dl)              9.2       11.5         7.1         8.4        9.4       10.1         8.4         8.6
  Leukocytes ( × 10^3^/μl)      13.7       13.8         3.8         0.2        4.4       3.9         21.6         1.7
  Thrombocytes ( × 10^3^/μl)     42        112          72           12        115        21          32           9

Abbreviations: +AHCST, after allogeneic hematopoietic stem cell transplantation; MF 0--3, grade of myelofibrosis; P, patient; PMF, primary myelofibrosis; WT, wild type.
